Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

News Conference News ACC 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

Todd Neale

April 05, 2022

Presentation ACC 2022

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

Presenter: Duk-Woo Park

April 04, 2022

News Conference News ACC 2021

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

Michael O'Riordan

May 17, 2021

News Conference News ACC 2021

ATLANTIS: Apixaban Has No Benefit Over Standard of Care Post-TAVI

Yael L. Maxwell

May 15, 2021

News Conference News ACC 2020

A-fib Patients Undergoing TAVR Do Better With OAC Alone: POPular TAVI

Todd Neale

March 29, 2020

News Conference News ACC 2019

My Takeaways From ACC 2019: Breaking With Embargoes? Despite the Drama, Embargoes Set to Stay

Shelley Wood

April 05, 2019

News Conference News ACC 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Michael O'Riordan

March 19, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Three

Shelley Wood

March 19, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Two

Shelley Wood

March 18, 2017

News Opinion Editor's Corner ACC 2016

Hot or Not, This Year’s Trials Offer Food for Thought: My Takeaways From ACC 2016

Shelley Wood

April 13, 2016

News Conference News ACC 2014

ACC/i2 2014: Cardiologists Carefully Consider TAVR, Renal Denervation

Yael L. Maxwell

April 03, 2014

News Conference News ACC 2014

CHOICE Trial, TVT Registry Shed Light on Evolving TAVR Outcomes, Risks

L.A. McKeown

March 31, 2014

Advertisement

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

ATLANTIS: Apixaban Has No Benefit Over Standard of Care Post-TAVI

A-fib Patients Undergoing TAVR Do Better With OAC Alone: POPular TAVI

My Takeaways From ACC 2019: Breaking With Embargoes? Despite the Drama, Embargoes Set to Stay

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Live From Washington: ACC 2017, Day Three

Live From Washington: ACC 2017, Day Two

Hot or Not, This Year’s Trials Offer Food for Thought: My Takeaways From ACC 2016

ACC/i2 2014: Cardiologists Carefully Consider TAVR, Renal Denervation

CHOICE Trial, TVT Registry Shed Light on Evolving TAVR Outcomes, Risks

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content